Genetics of familiar hypertrophic cardiomyopathy

被引:4
|
作者
Bonne, G [1 ]
Carrier, L [1 ]
Richard, P [1 ]
Hainque, B [1 ]
Tesson, F [1 ]
Komajda, M [1 ]
Schwartz, K [1 ]
机构
[1] Grp Hosp Pitie Salpetriere, INSERM, U153, F-75651 Paris 13, France
来源
M S-MEDECINE SCIENCES | 1998年 / 14卷 / 10期
关键词
D O I
10.4267/10608/910
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Familial hypertrophic cardiomyopathy (FHC) is characterized by left and/or right ventricular hypertrophy, preferentially affecting the interventricular septum, in the absence of other known causes that induce hypertrophy. Typical morphological changes include myocyte hypertrophy and disarray surrounding areas of loose connective tissue. Arrhythmias and premature sudden deaths are common. The clinical manifestations of FHC are numerous, ranging from benign asymptomatic course to severe heart failure and sudden death. FHC is inherited in an autosomal dominant pattern. The results of molecular genetic studies have shown that all mutations found so far concern genes that encode sarcomeric proteins: three contractile proteins, the beta-myosin heavy chain, the ventricular myosin essential light chain 1 and the ventricular myosin regulatory light chain 2; three associated proteins, cardiac troponin T, cardiac troponin I, and alpha-tropomyosin; and finally one myosin-binding protein, the cardiac myosin binding protein C. These genes certainly do not represent the whole spectrum of FHC disease genes since an additional locus was reported and one might reasonably hypothesize that disease genes yet to be identified include additional components of the sarcomere. One of the next challenges is to decipher the mechanisms through which the disease results from sarcomeric gene defects. The focus of the present article is to review the current state of knowledge on (1) the organization and mutations of FHC disease genes and proteins and (2) the in vitro and in vivo functional consequences of these mutations.
引用
收藏
页码:1054 / 1066
页数:13
相关论文
共 50 条
  • [41] Possible new homoplasmic mutation of mtDNA as the aetiology of a familiar hypertrophic cardiomyopathy
    Tettamanti, M. E.
    Berardo, A.
    Martin Casanueva, M. A.
    Blazquez, A.
    Kleppe, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 178 - 179
  • [43] Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging
    Ioana Danuta Muresan
    Lucia Agoston-Coldea
    Heart Failure Reviews, 2021, 26 : 1023 - 1036
  • [44] Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy
    Mathew, J.
    Zahavich, L.
    Lafreniere-Roula, M.
    Wilson, J.
    George, K.
    Benson, L.
    Bowdin, S.
    Mital, S.
    CLINICAL GENETICS, 2018, 93 (02) : 310 - 319
  • [45] Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment
    Butters, Alexandra
    Lakdawala, Neal K.
    Ingles, Jodie
    CURRENT HEART FAILURE REPORTS, 2021, 18 (05) : 264 - 273
  • [46] Factors Associated with Uptake of Genetics Services for Hypertrophic Cardiomyopathy
    Khouzam, Amirah
    Kwan, Andrea
    Baxter, Samantha
    Bernstein, Jonathan A.
    JOURNAL OF GENETIC COUNSELING, 2015, 24 (05) : 797 - 809
  • [47] Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment
    Alexandra Butters
    Neal K. Lakdawala
    Jodie Ingles
    Current Heart Failure Reports, 2021, 18 : 264 - 273
  • [48] Influence of genetics in sudden death risk in hypertrophic cardiomyopathy
    Romero Puche, A. J.
    Perez Sanchez, I.
    Oliva, M. J.
    Ruiz Espejo, F.
    Gomez Milanes, I.
    Garcia Molina, E.
    Sabater, M.
    Lacunza, J.
    Gimeno, J. R.
    Valdes, M.
    EUROPEAN HEART JOURNAL, 2012, 33 : 196 - 197
  • [49] Diagnosis of hypertrophic cardiomyopathy: Validation of criteria by genetics.
    Charron, P
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1998, 91 (12): : 65 - 68
  • [50] RECENT ADVANCES IN THE MOLECULAR-GENETICS OF HYPERTROPHIC CARDIOMYOPATHY
    MARIAN, AJ
    ROBERTS, R
    CIRCULATION, 1995, 92 (05) : 1336 - 1347